Italy Colorectal Cancer Screening: Participation Rates Show Regional Divide

Colorectal cancer screening participation rates in Italy reveal a stark geographic divide, with the Osservatorio Nazionale Screening reporting an overall average participation of 35.8% in 2024, contrasting sharply with regional peaks reaching 46.8% in Northern regions and dropping as low as 5.2% in Calabria. While organised prevention programs invite nearly 8 million individuals aged 50 to 69 (in some regions up to 74) every two years for a free fecal occult blood test, adherence remains critically low across large parts of the country, highlighting deep structural disparities in public health outreach.

Geographic Disparities and Regional Adherence Gaps

The national participation average masks extreme regional inequalities documented by official health monitoring. According to Istituto Superiore di Sanità surveillance data from the Passi monitoring system for 2023 to 2024, 47% of Italians aged 50 to 69 reported being up to date with colorectal screening. That figure breaks down into 62% in the North, 55% in the Center, and just 30% in the South.

Active promotion by healthcare operators plays a decisive role in these outcomes. Data shows that 67% of the target population received at least one intervention, such as an invitation letter from the local health authority or advice from a healthcare worker.

Clinical Evidence and the Impact of the NordICC Trial

Scientific debates regarding the efficacy of screening methods have evolved alongside new clinical data. Writing in his book Guida critica alla prevenzione, general practitioner Renato Luigi Rossi notes that colorectal cancer represents an ideal candidate for prevention because 10 to 15 years typically pass between the formation of an adenoma and its malignant transformation, allowing endoscopic removal to act as primary prevention rather than early diagnosis alone.

Randomized trials on flexible sigmoidoscopy demonstrate an 18% to 33% reduction in cancer incidence and a 26% to 50% reduction in mortality. However, the 2022 NordICC randomized trial across Norway, Sweden, and Poland challenged previous observational estimates by showing that invited participants experienced an 18% reduction in cancer risk, but a mortality reduction of only 10%, which lacked statistical significance. The trial suffered from low adherence, with only 42% of invitees actually undergoing colonoscopy.

A 13-year follow-up of the NordICC study published in May 2026 confirmed that colonoscopy continues to reduce cancer incidence, though mortality reductions remained statistically non-significant even among those who completed the procedure, a phenomenon authors attribute to general improvements in cancer treatment outcomes.

New American Guidelines and the Limitations of Blood Tests

Updated guidelines released in 2026 by the American Cancer Society and published in CA: A Cancer Journal for Clinicians emphasize high-sensitivity stool tests, multitarget stool DNA tests, and structural examinations like colonoscopy.

Blood-based screening tests are included in the American guidelines, though with a separate recommendation restricting their use exclusively to individuals who refuse or fail to complete preferred screening options. Data reported by JAMA indicates that some media presented the blood tests as an equivalent alternative, though a positive test still requires a colonoscopy.

In Italy, the reliance on opportunistic colonoscopies performed outside organized screening pathways is marginal (about 8%). Public health experts emphasize that introducing new diagnostic tools or expanding age thresholds will fail without first strengthening foundational infrastructure, ensuring punctual invitations, and building local trust, particularly in Southern regions.